Enter your terms above and click the 'Search' button.

Showing articles 0 to 13 of 13 Filter Applied: multiple sclerosis,relapsing (Click to remove) Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis JAMA 32:175-187, Brown, J.W.L.,et al, 2019 Natalizumab-Associated PML Neurol 88:1197-1205, Schwab, N.,et al, 2017 Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017 Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review JNNP 84:420-426, La Mantia, L.,et al, 2013 Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study Arch Neurol 66:593-599, Boster,A.,et al, 2009 Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008 Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008 Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007 How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS? Neurol 69:1498-1507, Brown,M.G.,et al, 2007 Mitoxantrone for Multiple Sclerosis in Clinical Practice Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004 The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis Neurol 61:1332-1338, Goodin,D.S.,et al, 2003 Relapses and Progression of Disability in Multiple Sclerosis NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000 Management of Multiple Sclerosis NEJM 337:1604-1611, Rudick,R.A.,et al, 1997 Showing articles 0 to 13 of 13